BioCardia, Inc.

This 8-K filing centers on a pivotal regulatory milestone: BioCardia’s formal submission of the CardiAMP HF clinical trial data to the FDA and its request for a meeting this quarter to discuss an accelerated approval pathway for the CardiAMP® System in ischemic chronic heart failure with reduced ejection fraction (HFrEF). The meeting will occur under the FDA’s Breakthrough Therapy designation — a status reserved for therapies that demonstrate substantial improvement over available alternatives for serious conditions — underscoring the agency’s prior recognition of the therapy’s potential. The company explicitly states its intent to seek approval based on three pillars: the safety profile observed in the trial, the well-characterized clinical response across 125 enrolled ischemic HFrEF patients, and the pronounced benefit seen in a prespecified high-risk subgroup defined by elevated biomarkers of heart stress. In that subgroup, CardiAMP delivered statistically significant and clinically meaningful outcomes — including a 47% relative risk reduction in all-cause cardiac death and a 37% reduction in non-fatal major adverse cardiac events — on top of stable guideline-directed medical therapy. These results were recently presented at the Technology and Heart Failure Therapeutics (THT) 2026 Annual Meeting, lending external scientific credibility. While the press release contains forward-looking statements about FDA feedback and approval likelihood, the filing itself confirms concrete, near-term regulatory engagement — a material catalyst for investors assessing clinical de-risking, commercial timeline, and valuation inflection points. No financial results, executive changes, or financing terms are disclosed; the event’s significance lies entirely in its regulatory progression and the strength of the subgroup efficacy signal.